Gene Therapy Explained: How Genes Are Delivered and What Makes It Work

Gene therapy offers a way to treat certain diseases not just by addressing symptoms, but by targeting the genetic instructions within human cells. However, creating a functional DNA sequence is not enough: it must be delivered precisely where it's needed, cross the cell membrane, and be used by the cell. To achieve this, scientists use specialized delivery systems-from modified viruses to non-viral nanoparticles.

What Is Gene Therapy and What Does It Change?

Gene therapy is a treatment approach where genetic material is introduced into human cells to alter their function. The goal can be to compensate for a faulty gene, add a new function, or modify the activity of existing genes.

Genes are segments of DNA that contain instructions for making proteins and other functional molecules. If a key gene is mutated, a cell may produce a defective protein, not make enough of it, or lose the ability to produce it altogether. This can cause inherited diseases.

One of the most straightforward approaches to gene therapy is delivering a working copy of a gene into a cell. The original, damaged DNA does not necessarily have to be removed; instead, the cell receives an extra genetic instruction to produce the normal protein.

Other strategies exist as well. The introduced genetic material can reduce the activity of an unwanted gene, affect the function of specific cells, or force them to produce a therapeutic protein. Thus, the term "gene therapy" encompasses several different technologies, not just a single universal treatment.

Choosing the right target cells is especially important. If a disease is related to liver, muscle, blood, or retinal cells, the genetic construct must be delivered to the appropriate tissue. Simply introducing the therapeutic gene into the body does not guarantee successful treatment.

Gene Therapy vs. Gene Editing: What's the Difference?

Gene therapy is often confused with genome editing, but these are not the same. Classical gene therapy may simply add a working copy of a gene to a cell without changing the original DNA sequence. Gene editing, in contrast, involves deliberately modifying a specific section of the genome.

Modern genetic editors allow for the deletion, replacement, or precise alteration of individual DNA sequences. For a deeper look at these technologies and next-generation genome editing, see our article: Next-Generation Genetic Editors: Alternatives to CRISPR and Precision DNA Editing.

Even the most precise editing system faces the same core challenge as classical gene therapy: the molecular tool must be delivered inside the right cell. That's why delivery technologies remain a crucial part of the field.

How Corrected Genes Are Delivered into Cells

The main challenge of gene therapy is not just making the desired DNA sequence, but delivering it. Genetic material is a large and fragile molecule that cannot easily pass through the cell membrane and is quickly broken down by enzymes in the extracellular environment.

To solve this, gene delivery requires a special carrier-a vector. This protects the genetic construct and helps it enter specific cells. Depending on the task, the vector may be a modified virus, a lipid particle, or another system capable of transporting DNA or RNA.

After entering the body, the carrier faces several barriers: it must reach the target tissue, attach to a cell, cross the membrane, and release the genetic material inside. In some cases, the DNA must also enter the nucleus, where the cell's genome is housed.

It's not enough to deliver the corrected gene "anywhere." Treating a muscle disorder requires targeting muscle cells; liver disease, liver cells; and blood disorders, the relevant blood cells or their precursors. The precision of this targeting directly affects both the efficacy and safety of therapy.

Direct Delivery into the Body: In Vivo

With the in vivo approach, the genetic construct is delivered directly into the patient. The vector spreads throughout the body and must reach the right tissue.

The method of administration depends on the disease. The vector may be injected into the bloodstream or locally into a specific tissue. Local delivery concentrates the treatment where it is needed and reduces effects on other cells.

Once the vector contacts a cell, it enters and releases the genetic material. The cell then uses the new instructions to synthesize the needed protein or therapeutic product.

The main advantage of in vivo therapy is the ability to target cells that cannot be conveniently removed from the body and returned. However, it's harder to control exactly which cells receive the construct and how strong an immune response the delivery system may trigger.

Modifying Cells Outside the Body: Ex Vivo

With the ex vivo approach, the required cells are first taken from the patient. In the lab, they are given the genetic material, checked, and only then returned to the body.

This method allows tighter control: researchers can confirm that the cells received the correct construct, assess their health, and select the best cells for reintroduction.

Ex vivo is especially suited for blood cells and their precursors, as these are relatively easy to extract, grow, and return. The same principle is used in creating genetically modified immune cells.

However, not every cell type can be safely removed, modified, and returned. The choice between in vivo and ex vivo depends on the disease, target cell type, and required control of the delivery process.

Viral Vectors: Turning Viruses into Gene Carriers

Viruses naturally penetrate cells and deliver their own genetic material. This property is harnessed in gene therapy, turning viruses into delivery vehicles for therapeutic DNA or RNA.

To do this, the virus is modified: the genes necessary for replication and disease are removed or deactivated, and the therapeutic sequence is inserted instead. The result is a viral vector-a carrier that can enter the cell and deliver the genetic payload, but cannot behave like a normal infectious virus.

It's important to understand that the viral vector does not "correct" the gene by itself. Its job is to deliver the DNA or RNA into the cell. The introduced construct then works according to the therapy's mechanism.

The efficiency of delivery depends on which cells the virus can infect. Different vectors have different "tropism"-a preference for certain tissues and cells. Thus, vector choice depends on both the size of the gene and where it needs to be delivered.

AAV and Other Viral Vectors

One of the best-known examples is the adeno-associated virus (AAV). AAVs can enter various cell types and are widely used for gene delivery.

The main feature of AAV vectors is that the delivered genetic material usually remains in the nucleus, separate from the cell's DNA. This lowers the risk of accidentally changing the genome, although the effect may weaken over time in actively dividing cells.

AAVs also have a key limitation: limited capacity. Large genes may not fit inside a single vector, necessitating other delivery systems or splitting the construct into parts.

Lentiviral vectors work differently: they integrate the delivered genetic material into the cell's DNA. This means the new sequence can be retained even after cell division, which is especially important for blood cells and their precursors.

However, integration requires strict safety controls. If a new sequence lands near a vital gene and alters its activity, this may disrupt cell function. Such systems are therefore carefully designed and tested.

There are also adenoviral vectors. These can carry larger genetic constructs and infect cells efficiently, but may provoke a strong immune response, limiting their use to certain tasks.

In summary, there is no universal viral vector. Some systems are better for long-term cell modification, others for temporary delivery, and others for specific tissues or larger constructs. Choosing the right carrier is as important as choosing the therapeutic gene itself.

Can Genes Be Delivered Without Viruses?

Viral vectors are effective, but they are not the only way to deliver genes. Non-viral methods are actively developed, using lipid particles, polymers, and other synthetic carriers.

One well-known technology is lipid nanoparticles. Their shell consists of fat molecules that surround and protect the DNA or RNA. After contacting a cell, the particle can enter and release its genetic payload.

A similar approach uses polymeric carriers. Special molecules bind to DNA or RNA, forming compact complexes that are easier to transport through biological barriers. The makeup of these systems can be adjusted for stability, circulation time, and cell interactions.

The main advantage of non-viral delivery is flexibility. Synthetic carriers can be tailored for a specific task-adjusting size, chemistry, and cargo amount. They also lack viral shells, reducing some immunological risks.

Another benefit: non-viral systems are usually easier to adapt for delivering various types of genetic material. They can carry not only DNA but also different forms of RNA, including molecules that work temporarily and then degrade inside the cell.

However, for certain tissues, non-viral methods may not match the efficiency of viral vectors. It's not enough just to enter the cell: the carrier must avoid destruction, escape cellular compartments, and deliver cargo to the right location.

Targeted delivery remains a challenge. Once in the bloodstream, particles distribute unevenly; some organs take them up more than others. Researchers are developing coatings and molecular "tags" to help carriers better interact with the desired cell types.

Thus, non-viral and viral methods do not so much replace each other as solve different problems. For high-efficiency delivery to a particular tissue, viral vectors may be preferable. When flexibility, repeat dosing, or temporary activity is needed, non-viral delivery may have the edge.

What Happens to the Genome After Delivery and How Safe Is Gene Therapy?

Once the vector reaches the target cell and enters it, the next stage is the release of the genetic material. The carrier has completed its main job; the result now depends on where the DNA or RNA ends up and how well the cell can use it.

If the therapy is DNA-based, the construct usually must enter the cell's nucleus. There, it may remain separate from the chromosomes or, depending on the vector, integrate into the genome. The cell's machinery then reads the new instruction and starts making the desired protein.

For RNA-based therapy, the path is shorter: the RNA works directly in the cytoplasm, where proteins are made. RNA degrades over time, so the effect is usually temporary-sometimes an advantage if permanent cell changes aren't needed.

The duration of gene therapy depends not only on the type of genetic material but also on the cells themselves. In slow-dividing tissues, the effect may last longer; in fast-renewing tissues, the effect may fade if the new gene isn't passed to daughter cells.

For successful treatment, it's crucial to achieve the right level of gene activity. Too little therapeutic protein may be ineffective; too much can disrupt normal cell function.

Limitations and Risks

One key risk is the immune system. The body may recognize the viral vector or its components as foreign and try to destroy them. A strong immune response can reduce delivery effectiveness and increase unwanted reactions.

Pre-existing immunity is also an issue: if someone has previously encountered a similar virus, antibodies can quickly neutralize the vector before it reaches target cells. This makes repeated use of some viral systems harder than the first dose.

Another risk comes from integrating genetic material into the genome. If a new sequence lands near an important gene and alters its activity, it may disrupt the cell. Modern vectors are designed to minimize such risks, but biological risk cannot be eliminated entirely.

There's also a size limit: some vectors cannot physically hold a large gene, so researchers must use different delivery systems or more complex constructs.

Distribution throughout the body is another challenge. Even when a vector is designed for a particular tissue, some particles may end up in other organs. Thus, the safety of gene therapy depends heavily on how precisely the delivery system targets the right cells and how well gene activity is controlled.

For these reasons, gene therapy is not simply "replacing a bad gene with a good one." It's a complex, multi-step process where results depend on the genetic construct, delivery method, cell type, and the body's response.

Conclusion

Gene therapy works not only by creating the right genetic sequence, but also by being able to deliver it to the correct cells. First, a therapeutic gene or construct is chosen; then, a suitable vector is selected; and finally, the material must overcome biological barriers, enter the cell, and function as intended.

Both viral and non-viral delivery systems are used. AAV, lentiviral, and adenoviral vectors use the natural ability of viruses to enter cells, while lipid nanoparticles and other synthetic carriers deliver DNA and RNA without a viral shell.

No universal method exists. For some diseases, long-term gene activity is crucial; for others, temporary action, repeat dosing, or precise tissue targeting is more important. The effectiveness of therapy largely depends on choosing the right delivery method.

The main challenge in modern gene therapy is not just learning to modify genetic information, but doing so accurately, safely, and only in the desired cells. The development of new delivery systems will largely determine how widely these methods can be used in medicine.

FAQ

1. What is gene therapy in simple terms?
   Gene therapy is a treatment method where genetic material is delivered into human cells to change how they function. For example, a working copy of a gene can be given to a cell if its own gene is damaged and cannot produce the necessary protein.
2. How are genes delivered into human cells?
   Special carriers called vectors are used to deliver genes. These can be modified viruses, lipid nanoparticles, or other systems that protect DNA or RNA and help them cross the cell membrane.
3. What is a viral vector in gene therapy?
   A viral vector is a specially modified virus used as a delivery vehicle for genetic material. Components required for infection are removed or disabled, and the therapeutic gene construct is inserted instead.
4. How is gene therapy different from gene editing?
   Gene therapy can add a new working copy of a gene to a cell without changing the original DNA sequence. Gene editing involves directly altering a specific part of the genome, such as replacing or correcting a particular sequence.
5. Is gene therapy safe?
   Safety depends on the type of therapy, the vector used, the target cells, and the body's response. Immune reactions, delivery challenges, and other unwanted effects are possible, so gene therapy methods require thorough testing and medical oversight.